Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alogliptin Rejection Dents Takeda’s Diabetes Franchise

This article was originally published in The Pink Sheet Daily

Executive Summary

Latest “complete response” letter for Takeda’s DPP-4 inhibitor is “not specific” to cardiovascular outcomes. But the delay does not bode well for entry into the crowded DPP-4 space.

You may also be interested in...



Use Of Pre-Approval CV Data From Ongoing Trial Gets Once-Over At Canagliflozin Panel

There is no statistical reason not to allow a single trial to provide pre-approval and post-approval cardiovascular hazard ratios for a diabetes drug, FDA says, but Janssen’s canagliflozin would be the first. The Endocrinologic and Metabolic Drugs Advisory Committee backed approval 10-5.

Merck Committed To Animal Health, Consumer Care, Frazier Says

In a week that saw Pfizer sell a non-core business to Nestle for five times sales, CEO Ken Frazier says Merck’s non-core businesses “complement” its R&D-driven pharma business.

Merck Committed To Animal Health, Consumer Care, Frazier Says

In a week that saw Pfizer sell a non-core business to Nestle for five times sales, CEO Ken Frazier says Merck’s non-core businesses “complement” its R&D-driven pharma business.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074072

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel